Blog
RSS FeedPosted by Michael Wonder on 05 Sep 2023
NICE recommends Chiesi’s Elfabrio for adults with Fabry disease
4 September 2023 - NICE has recommended Chiesi’s Elfabrio (pegunigalsidase alfa) as a long-term option for treating Fabry disease in ...
Posted by Michael Wonder on 01 Sep 2023
Efgartigimod for the treatment of patients with generalised myasthenia gravis
1 September 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 23 Aug 2023
Dupilumab for the treatment of patients with prurigo nodularis
23 August 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 18 Aug 2023
NICE draft guidance recommends novel treatment for debilitating inherited skin condition
18 August 2023 - Around 670 people in England with painful and debilitating skin wounds caused by a rare inherited disorder ...
Posted by Michael Wonder on 17 Aug 2023
Keytruda backed for 'basket' of new cancers via NHS
17 August 2023 - The UK's cost effectiveness agency NICE has recommended MSD's PD-1 inhibitor Keytruda for a series of ...
Posted by Michael Wonder on 15 Aug 2023
Cipaglucosidase alfa and miglustat for the treatment of patients with late-onset Pompe disease
15 August 2023 - NICE has published evidence-based recommendations on the use of cipaglucosidase alfa (Pombiliti) with miglustat (Opfolda) for ...
Posted by Michael Wonder on 07 Aug 2023
GP leaders advise practices not to prescribe cholesterol lowering drug inclisiran
1 August 2023 - Local GP leaders across the south of England have told practices not to follow the NHS’s ...
Posted by Michael Wonder on 04 Aug 2023
Setmelanotide acetate for the treatment of people with obesity and hyperphagia associated with Bardet-Biedl syndrome
3 August 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 02 Aug 2023
Etranacogene dezaparvovec for the treatment of patients with moderately severe or severe haemophilia B
2 August 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 02 Aug 2023
Ganaxolone for the treatment of patients with seizures caused by CDKL5 deficiency disorder
2 August 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Aug 2023
Zanubrutinib for the treatment of patients with chronic lymphocytic leukaemia
1 August 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Jul 2023
Talazoparib tosylate for the treatment of patients with advanced, germline BRCA mutation positive, HER2 negative breast cancer
28 July 2023 - NICE has published preliminary evidence-based recommendations on the use of talazoparib tosylate (Talzenna) for the treatment of ...
Posted by Michael Wonder on 26 Jul 2023
Afamelanotide acetate for the treatment of patients with erythropoietic protoporphyria
27 July 2023 - NICE has published final evidence-based recommendations on the use of afamelanotide acetate (Scenesse) for the treatment ...
Posted by Michael Wonder on 26 Jul 2023
Selpercatinib for untreated RET fusion positive advanced non-small-cell lung cancer
26 July 2023 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for adults with advanced, ...
Posted by Michael Wonder on 20 Jul 2023
New Government consultation on medicine clawbacks will harm investment, says ABPI
19 July 2023 - In a move that will further damage UK life sciences investment, the Government has launched a ...